



Press Release Contact Information:

Brian Meshkin
Salugen, Inc.
President
4660 La Jolla Village Drive, Suite 500
San Diego, California
USA, 92122
Voice: 877-258-4360
Fax: 877-258-4360
E-Mail: [Email us Here](mailto:info@salugen.com)
Website: [Visit Our Website](http://www.salugen.com)

Salugen Announces Scientific Publication to Explain Potential Role of COMT Gene in Craving Behaviors

Salugen publishes findings in peer-reviewed medical journal to suggest how COMT genetic analysis and targeted nutritional interventions may prevent relapse in excess cravings disorders

/24-7PressRelease/ - SAN DIEGO, CA, July 16, 2008 - Salugen, Inc. (www.salugen.com), a life sciences company, announces today a scientific publication to support its core anti-craving nutrigenomic technology. In a peer-reviewed medical journal, the study authors suggest how genetic analysis and manipulation of a brain enzyme through nutritional ingredients can reduce excess craving behavior and prevent relapse in the Top 3 Leading Causes of Preventable Death in the United States. In the peer-reviewed medical journal, *Medical Hypotheses*, the article is entitled "Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: A hypothesis." In this publication, Salugen researchers from Wake Forest University School of Medicine and universities in Taiwan and Spain suggest that Salugen's core technology involving a proprietary nutrient formulation, combined with its patent-protected DNA analysis may be a useful adjunct to therapy when used in outpatient recovery.

Study authors state that an important enzyme, catechol-o-methyl transferase (COMT) activity, relies on gene polymorphisms. Study authors explain that earlier studies from Salugen's researchers showed a significant reduction in relapse rates when using an earlier version of its nutritional formulation in outpatient DUI offenders with either alcohol or cocaine-related problems. They went on to explain that in a more recent study with some additional ingredients, the recovery rate was 79.1%, out of 76 patients (alcohol and methamphetamine related) attending a 12 month program.

While further studies are warranted, Salugen researchers suggest that these data coupled together, along with additional studies completed and ongoing, continue to support the value of Salugen's core technology to identify the underlying genetic factors of excess cravings and then provide an adjunct treatment for associated conditions.

About Salugen, Inc.

Salugen is a life sciences company offering nutritional ingredients and gene testing to help reduce excessive cravings involved in smoking, weight problems, and alcohol and drug abuse. Salugen has a patent-protected, clinically proven nutritional formulation to reduce stress and cravings, as well as patent-protected gene tests to help identify these persons and customize their treatment. Simply, Salugen's goal is to reduce or eliminate the illness, costs, and deaths associated with these preventable disorders. The company has headquarters in San Diego, CA. For additional information about the company, please visit <http://www.salugen.com>.